Xencor, Inc. (NASDAQ: XNCR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -2.29 | Insider Own | 17.35% | Shs Outstand | 74.14M | Perf Week | 3.96% |
| Market Cap | 1.50B | Forward P/E | - | EPS next Y | -3.18 | Insider Trans | -0.63% | Shs Float | 54.42M | Perf Month | 31.40% |
| Enterprise Value | 1.66B | PEG | 0.13 | EPS next Q | - | Inst Own | - | Short Float | 19.92% | Perf Quarter | 69.40% |
| Income | -169.92M | P/S | 15.39 | EPS this Y | -67.41% | Inst Trans | - | Short Ratio | 13.22 | Perf Half Y | 63.25% |
| Sales | 97.36M | P/B | 2.95 | EPS next Y | 17.09% | ROA | -23.40% | Short Interest | 10.84M | Perf YTD | 32.01% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -28.77% | 52W High | 20.89 -7.12% | Perf Year | 131.50% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -30.58% | 52W Low | 6.64 192.05% | Perf 3Y | -16.73% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -8.60% 0.48% | Gross Margin | 36.15% | Volatility | 7.03% 7.53% | Perf 5Y | -36.57% |
| Dividend TTM | - | EV/Sales | 17.04 | EPS Y/Y TTM | 36.03% | Oper. Margin | -217.93% | ATR (14) | 1.31 | Perf 10Y | 8.42% |
| Dividend Ex-Date | - | Quick Ratio | 6.57 | Sales Y/Y TTM | -10.91% | Profit Margin | -177.10% | RSI (14) | 65.74 | Recom | 2.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.57 | EPS Q/Q | -159.09% | SMA20 | 13.83% | Beta | 0.84 | Target Price | 27.00 |
| Payout | 0.00% | Debt/Eq | 0.34 | Sales Q/Q | -84.85% | SMA50 | 36.89% | Rel Volume | 1.39 | Prev Close | 20.21 |
| Employees | 260 | LT Debt/Eq | 0.22 | Earnings | Aug 05 | SMA200 | 46.37% | Avg Volume | 930.26K | Price | 19.40 |
| IPO Date | Dec 03, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -106.38% -83.79% | Net Debt/EBITDA | -1.22 | Volume | 1,296,342 | Change | -4.01% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-07-26 | Reiterated | Truist Securities | Buy | $29 → $27 |
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Dec-17-25 | Reiterated | Barclays | Overweight | $23 → $26 |
| Nov-24-25 | Initiated | Truist | Buy | $29 |
| Nov-06-25 | Reiterated | Cantor Fitzgerald | Overweight | $42 |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight | $6.00 → $23 |
| Oct-27-25 | Reiterated | RBC Capital | Outperform | $31 → $18 |
| Sep-16-25 | Reiterated | Barclays | Underweight | $6.00 |
| Sep-03-25 | Downgrade | B of A Securities | Buy → Neutral | |
| Aug-07-25 | Reiterated | Wedbush | Outperform | $31 → $26 |
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 98 | 126 | 110 | 175 | 165 | 275 | 123 | 157 | 41 | |
| Cost of Goods Sold Incl. D&A | 63 | 11 | 228 | 0 | 200 | 193 | 170 | 119 | 98 | |
| Gross Profit | 36 | 115 | -117 | 175 | -35 | 83 | -47 | 38 | -57 | |
| Selling, General and Administrative Excl. Other | 64 | 64 | 59 | 53 | 47 | 39 | 30 | 24 | 22 | |
| Research and Development | 246 | 239 | 228 | 254 | 200 | 193 | 170 | 119 | 98 | |
| Other Operating Expense | -63 | -10 | -226 | 0 | -200 | -193 | -170 | -119 | 0 | |
| Operating Income | -213 | -178 | -178 | -132 | -82 | 44 | -77 | 14 | -79 | |
| Interest Expense | 28 | 32 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 70 | 120 | -20 | 13 | 28 | 39 | 7 | 13 | 9 | |
| Net Income Before Taxes | -170 | -89 | -235 | -120 | -55 | 83 | -69 | 27 | -70 | |
| Income Taxes | 2 | 3 | 2 | 14 | 1 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -173 | -92 | -233 | -133 | -55 | 83 | -69 | 27 | -70 | |
| Net Income From Continuing Operations | -173 | -92 | -237 | -133 | -55 | 83 | -69 | 27 | -70 | |
| Net Income | -173 | -92 | -233 | -133 | -55 | 83 | -69 | 27 | -70 | |
| EPS (Recurring) | -2.29 | -1.24 | -3.58 | -2.08 | -0.93 | 1.42 | -1.11 | 0.48 | -1.31 | |
| EPS (Basic, Before Extraordinaries) | -2.29 | -1.24 | -3.58 | -2.08 | -0.93 | 1.42 | -1.11 | 0.48 | -1.31 | |
| EPS (Diluted) | -2.29 | -1.24 | -3.58 | -2.08 | -0.93 | 1.37 | -1.11 | 0.46 | -1.31 | |
| EBITDA | -131 | -47 | -186 | -102 | -46 | 90 | -71 | 18 | -76 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | 29.28 | — | 74.76 | — | |
| Price To Sales Ratio | 14.85 | 8.99 | 13.58 | 7.40 | 9.47 | 8.46 | 20.22 | 12.49 | 47.63 | |
| Gross Margin | 36.73 | 91.27 | -106.36 | 100.00 | -21.21 | 30.18 | -38.21 | 24.20 | -139.02 | |
| Operating Margin | -217.35 | -141.27 | -161.82 | -75.43 | -49.70 | 16.00 | -62.60 | 8.92 | -192.68 | |
| Net Margin | -176.53 | -73.02 | -211.82 | -76.00 | -33.33 | 30.18 | -56.10 | 17.20 | -170.73 | |
| Shares Outstanding | 75 | 74 | 65 | 61 | 60 | 58 | 57 | 57 | 54 | |
| Market Capitalization | 1,455 | 1,133 | 1,494 | 1,295 | 1,562 | 2,327 | 2,487 | 1,960 | 1,953 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Feigal Ellen | Director | Jun 18 '26 | Sale | 13.06 | 6,843 | 89,370 | 12,340 | Jun 22 |
| GORMAN KEVIN CHARLES | Director | Jun 15 '26 | Sale | 12.31 | 7,527 | 92,657 | 11,378 | Jun 17 |
| GUSTAFSON KURT A | Director | Jun 15 '26 | Sale | 12.31 | 5,474 | 67,385 | 14,709 | Jun 17 |
| RANIERI RICHARD J | Director | Jun 15 '26 | Sale | 12.31 | 5,474 | 67,385 | 13,709 | Jun 17 |
| Montgomery Alan Bruce | Director | Jun 15 '26 | Sale | 12.31 | 5,064 | 62,338 | 15,547 | Jun 17 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | Apr 10 '26 | Sale | 12.29 | 3,499 | 42,990 | 75,898 | Apr 13 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO | Mar 06 '26 | Sale | 11.02 | 2,502 | 27,571 | 263,831 | Mar 09 |
| Eckert Celia | SVP, GENERAL COUNSEL | Mar 06 '26 | Sale | 11.02 | 1,767 | 19,472 | 76,918 | Mar 09 |
| Dahiyat Bassil I | PRESIDENT & CEO | Mar 06 '26 | Sale | 11.02 | 6,606 | 72,796 | 546,316 | Mar 09 |
| Eckert Celia | SVP, GENERAL COUNSEL | Mar 05 '26 | Sale | 11.25 | 3,244 | 36,480 | 78,685 | Mar 09 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO | Mar 05 '26 | Sale | 11.25 | 4,118 | 46,309 | 266,333 | Mar 09 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | Mar 05 '26 | Sale | 11.25 | 2,517 | 28,305 | 79,397 | Mar 09 |
| Dahiyat Bassil I | PRESIDENT & CEO | Mar 05 '26 | Sale | 11.25 | 14,870 | 167,221 | 552,922 | Mar 09 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO | Mar 03 '26 | Sale | 11.90 | 2,663 | 31,677 | 270,451 | Mar 04 |
| Eckert Celia | SVP, GENERAL COUNSEL | Mar 03 '26 | Sale | 11.90 | 1,492 | 17,747 | 81,929 | Mar 04 |